Aurinia Pharm Ord (AUPH) Stock Price, Quote & News

Company Profile

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement wit...

Industry: Biotechnology

Sector: Healthcare

Phone: 250 744 2487

Fax: 250 708 4345

Website: www.auriniapharma.com

Address:

#140, 14315 – 118 Avenue, Edmonton, Canada

3D_STOCK_TRADING Aug. 27 at 6:28 PM

$AUPH Peter "the PIG" Greenthief is micro dosing Ketamine to better understand how to screw over his retail investor... Obviously, he great connections to get his supply!!!!!

0 · Reply

Hopenitsgood Aug. 27 at 6:28 PM

$AUPH This stock will rocket faster than a fired cracker barrel CEO if Peter has a failed CABG.

0 · Reply

Hopenitsgood Aug. 27 at 6:27 PM

$AUPH How many people on here buying the dips? Lol. You dipbuyers must have about what? 2 3 million shares buy now? Peter here =share value not Peter gone= share value will rocket

1 · Reply

RedBarnCannabis Aug. 27 at 5:53 PM

$AUPH Tang's company significantly reduces stake in Cargo Therapeutics. Maybe use some of that cash for buying a bigger stake in AUPH.

1 · Reply

jdoldnumber7 Aug. 27 at 5:40 PM

$AUPH She's attempting to head North, much like yesterday...

2 · Reply

Solomonwisdom7 Aug. 27 at 4:56 PM

$AUPH It does make a long wonder?

1 · Reply

raptos21 Aug. 27 at 4:45 PM

$AUPH gotta wonder why $12 is the new magnet... Are they setting it up for 50-100% premium between $18-$24?

1 · Reply

sck2 Aug. 27 at 4:05 PM

$AUPH 🕵️‍♂️😊 ... 🐖

0 · Reply

sck2 Aug. 27 at 3:54 PM

$AUPH b o when?🐖

0 · Reply

Coffee_black Aug. 27 at 3:39 PM

$AUPH unbelieveable.

4 · Reply

Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)

Jul 31, 2025, 5:57 PM EDT - 26 days ago

Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 6:00 AM EDT - 27 days ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025

Jul 22, 2025, 6:00 AM EDT - 5 weeks ago

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

Jul 7, 2025, 12:49 PM EDT - 7 weeks ago

The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity

Jun 30, 2025, 6:00 AM EDT - 2 months ago

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

Jun 29, 2025, 5:00 PM EDT - 2 months ago

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

May 22, 2025, 6:00 AM EDT - 3 months ago

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

May 12, 2025, 12:56 PM EDT - 3 months ago

Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance

May 12, 2025, 11:04 AM EDT - 3 months ago

Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript

May 12, 2025, 6:00 AM EDT - 3 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

May 5, 2025, 6:00 AM EDT - 4 months ago

Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

Apr 30, 2025, 6:00 AM EDT - 4 months ago

Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

Apr 29, 2025, 6:00 AM EDT - 4 months ago

ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

Apr 26, 2025, 10:54 AM EDT - 4 months ago

Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth

Apr 23, 2025, 4:05 PM EDT - 4 months ago

Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting

Feb 27, 2025, 2:11 PM EST - 6 months ago

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations

Feb 27, 2025, 10:32 AM EST - 6 months ago

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 6:00 AM EST - 6 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

Feb 21, 2025, 4:09 PM EST - 6 months ago

Aurinia Pharmaceuticals: There's Still Time For Sales Growth

Feb 20, 2025, 4:05 PM EST - 6 months ago

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Jan 22, 2025, 12:29 PM EST - 7 months ago

3 Biotech Stocks With Notable Insider Buying

AZN COGT JAZZ ONC XBI ZYME

Nov 18, 2024, 5:53 PM EST - 10 months ago

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Nov 15, 2024, 6:00 AM EST - 10 months ago

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Nov 14, 2024, 6:00 AM EST - 10 months ago

Aurinia to Participate in Jefferies London Healthcare Conference

Nov 8, 2024, 12:15 PM EST - 10 months ago

Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon

Nov 7, 2024, 11:44 AM EST - 10 months ago

Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:10 AM EST - 10 months ago

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

Nov 7, 2024, 6:00 AM EST - 10 months ago

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Oct 30, 2024, 4:05 PM EDT - 10 months ago

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

Oct 11, 2024, 6:00 AM EDT - 11 months ago

Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024

Sep 24, 2024, 8:10 AM EDT - 1 year ago

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Sep 19, 2024, 12:54 PM EDT - 1 year ago

3 Small Biotech Stocks With The 'Big Mo' Right Now

CORT VRDN

Sep 19, 2024, 7:55 AM EDT - 1 year ago

Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment

Sep 18, 2024, 4:41 AM EDT - 1 year ago

Aurinia Pharmaceuticals: This Recovery Can Continue

Sep 13, 2024, 6:00 AM EDT - 1 year ago

Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Aurinia Announces Board Restructuring

Sep 5, 2024, 6:00 AM EDT - 1 year ago

Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Aug 28, 2024, 6:00 AM EDT - 1 year ago

Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board

Aug 1, 2024, 1:52 PM EDT - 1 year ago

Aurinia Pharmaceuticals, Inc. (AUPH) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results

Jul 19, 2024, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

Jul 11, 2024, 3:27 PM EDT - 1 year ago

ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders' Voices Expressed at the AGM

Jul 5, 2024, 2:10 PM EDT - 1 year ago

Aurinia Pharmaceuticals Appears Undervalued

Jul 2, 2024, 6:00 AM EDT - 1 year ago

Aurinia to Participate in Upcoming Investor Healthcare Conferences

Jun 14, 2024, 12:16 PM EDT - 1 year ago

Aurinia Announces 2024 Annual General Meeting Results

Jun 5, 2024, 6:00 AM EDT - 1 year ago

Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024

Jun 4, 2024, 5:30 PM EDT - 1 year ago

Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce

Jun 3, 2024, 6:30 PM EDT - 1 year ago

Aurinia Provides Update on Proxy Statement

3D_STOCK_TRADING Aug. 27 at 6:28 PM

$AUPH Peter "the PIG" Greenthief is micro dosing Ketamine to better understand how to screw over his retail investor... Obviously, he great connections to get his supply!!!!!

0 · Reply

Hopenitsgood Aug. 27 at 6:28 PM

$AUPH This stock will rocket faster than a fired cracker barrel CEO if Peter has a failed CABG.

0 · Reply

Hopenitsgood Aug. 27 at 6:27 PM

$AUPH How many people on here buying the dips? Lol. You dipbuyers must have about what? 2 3 million shares buy now? Peter here =share value not Peter gone= share value will rocket

1 · Reply

RedBarnCannabis Aug. 27 at 5:53 PM

$AUPH Tang's company significantly reduces stake in Cargo Therapeutics. Maybe use some of that cash for buying a bigger stake in AUPH.

1 · Reply

jdoldnumber7 Aug. 27 at 5:40 PM

$AUPH She's attempting to head North, much like yesterday...

2 · Reply

Solomonwisdom7 Aug. 27 at 4:56 PM

$AUPH It does make a long wonder?

1 · Reply

raptos21 Aug. 27 at 4:45 PM

$AUPH gotta wonder why $12 is the new magnet... Are they setting it up for 50-100% premium between $18-$24?

1 · Reply

sck2 Aug. 27 at 4:05 PM

$AUPH 🕵️‍♂️😊 ... 🐖

0 · Reply

sck2 Aug. 27 at 3:54 PM

$AUPH b o when?🐖

0 · Reply

Coffee_black Aug. 27 at 3:39 PM

$AUPH unbelieveable.

4 · Reply

Coffee_black Aug. 27 at 2:40 PM

$AUPH pathetic, everyday is pathetic.

0 · Reply

jdoldnumber7 Aug. 27 at 2:36 PM

$AUPH C'mon Tang, I think it's about time to buy another 1M shares. Make some calls, get your whale friends involved.

1 · Reply

Coffee_black Aug. 27 at 2:04 PM

$AUPH what a pile of horse manure.

0 · Reply

pikus Aug. 27 at 2:01 PM

$AUPH Added a bit more again

0 · Reply

Coffee_black Aug. 27 at 1:39 PM

$AUPH wow does this ever open up green lmfao. Fuck sakes, every day, same shit..

0 · Reply

TallyHo821 Aug. 27 at 1:38 PM

$AUPH Boy it’s nice every dip under $12 gets eaten up……positive signs !! Little resistance mid $12’s…..but let’s go!

0 · Reply

MRTunity Aug. 27 at 1:37 PM

$AUPH still long … that dip caught me off guard but HODL… need $12.60+ for major run 🛑 loss raised from $11.75 to $11.82 If we drop back to new lower lows, doesn’t bode well for rest of days momentum… Breaks above $12.60 PLUS I will be doubling down on my long position ‼️

0 · Reply

Coffee_black Aug. 27 at 12:50 PM

$AUPH who is this Nelly goof? Blocked. Bitch.

1 · Reply

Iwillplay Aug. 27 at 12:44 PM

$AUPH Take out that 12.31.

0 · Reply

Coffee_black Aug. 27 at 12:44 PM

$AUPH

0 · Reply

paperjam Aug. 27 at 12:12 PM

$AUPH "Meta-Analysis Supports Combination Therapy for Lupus Nephritis" - meta-analysis found that VCS + MPAA resulted in 281.38 more complete renal responses per 1000 patients vs belimumab (145.02), obinutuzumab (134.23) and tacrolimus (168.03) - with respect to safety outcomes, CTX, LEF, and TAC + MPAA were associated with higher infection risks compared with MMF alone. VCS and OBI combinations showed more modest infection increases (less than 100 extra cases), with uncertain effects on severe infections - “These findings support the growing body of evidence favoring these combinations as potential first-line therapies” https://www.renalandurologynews.com/news/lupus-nephritis-combination-therapy-meta-analysis-risk/ https://www.kireports.org/article/S2468-0249(25)00419-X/pdf

2 · Reply

pikus Aug. 27 at 12:02 PM

$AUPH

0 · Reply

Market Cap	1.60B
Revenue (ttm)	235.13M
Net Income (ttm)	5.75M
EPS (ttm)	N/A
PE Ratio	24.06
Forward PE	19.05
Profit Margin	2.45%
Debt to Equity Ratio	0.00

Volume	567,986
Avg Vol	2,284,978
Day's Range	N/A - N/A
Shares Out	131.63M
Stochastic %K	60%
Beta	1.23
Analysts	Strong Sell
Price Target	$11.71